Create a free QxMD account to receive personalized paper recommendations, relevant to your practice.

Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity

Roman Shapiro, Ian Chin-Yee, Selay Lam

Clinical Case Reports 2015, 3 (11): 942-4

Severe cold agglutinin disease with hemodynamic compromise requires rapid stabilization of the autoimmune hemolytic anemia as a bridge to the immunosuppressive effect of rituximab. Herein, we describe eculizumab treatment of severe complement-mediated hemolysis in a patient whose hemodynamic status deteriorated in spite of supportive blood transfusions and therapeutic plasma exchange.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

[Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature]. Z Adam, A Pejchalová, G Chlupová, L Ríhová, L Pour, M Krejčí, L Cervinek, Z Král, J Mayer Vnitr̆ní Lékar̆ství 2013, 59 (9): 828-40

Severe refractory autoimmune hemolytic anemia with both warm and cold autoantibodies that responded completely to a single cycle of rituximab: a case report. Shilpi Gupta, Anita Szerszen, Fadi Nakhl, Seema Varma, Aaron Gottesman, Frank Forte, Meekoo Dhar Journal of Medical Case Reports 2011, 5: 156

Treatment of autoimmune hemolytic anemias. L D Petz Current Opinion in Hematology 2001, 8 (6): 411-6

Cold agglutinin-mediated autoimmune hemolytic anemia. Sigbjørn Berentsen, Ulla Randen, Geir E Tjønnfjord Hematology/oncology Clinics of North America 2015, 29 (3): 455-71

Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease. A Vassou, V Alymara, A Chaidos, K L Bourantas International Journal of Hematology 2005, 81 (5): 421-3

Complement inhibitors to treat IgM-mediated autoimmune hemolysis. Diana Wouters, Sacha Zeerleder Haematologica 2015, 100 (11): 1388-95

Inefficacy of plasma exchange in cold agglutinin hemolytic anemia--a case study. S Rodenhuis, A Maas, C A Hazenberg, P C Das, H O Nieweg Vox Sanguinis 1985, 49 (1): 20-5

Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Mark Boonyasampant, Ilene C Weitz, Brian Kay, Chaiyaporn Boonchalermvichian, Howard A Liebman, Ira A Shulman Transfusion 2015, 55 (10): 2398-403

Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab. Joshua Ruch, Brandon McMahon, Glenn Ramsey, Hau C Kwaan American Journal of Hematology 2009, 84 (2): 120-2

Life-threatening hemolytic anemia due to an autoanti-Pr cold agglutinin: evidence that glycophorin A antibodies may induce lipid bilayer exposure and cation permeability independent of agglutination. Michael C Brain, Bernard Ruether, Karen Valentine, Christopher Brown, Henk ter Keurs Transfusion 2010, 50 (2): 292-301

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity

Discussion

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips